Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Muscle: an independent contributor to the neuromuscular spinal muscular atrophy disease phenotype
Narendra N. Jha, Jeong-Ki Kim, Yoon-Ra Her, Umrao R. Monani
Narendra N. Jha, Jeong-Ki Kim, Yoon-Ra Her, Umrao R. Monani
View: Text | PDF
Review

Muscle: an independent contributor to the neuromuscular spinal muscular atrophy disease phenotype

  • Text
  • PDF
Abstract

Spinal muscular atrophy (SMA) is a pediatric-onset neuromuscular disorder caused by insufficient survival motor neuron (SMN) protein. SMN restorative therapies are now approved for the treatment of SMA; however, they are not curative, likely due to a combination of imperfect treatment timing, inadequate SMN augmentation, and failure to optimally target relevant organs. Here, we consider the implications of imperfect treatment administration, focusing specifically on outcomes for skeletal muscle. We examine the evidence that muscle plays a contributing role in driving neuromuscular dysfunction in SMA. Next, we discuss how SMN might regulate the health of myofibers and their progenitors. Finally, we speculate on therapeutic outcomes of failing to raise muscle SMN to healthful levels and present strategies to restore function to this tissue to ensure better treatment results.

Authors

Narendra N. Jha, Jeong-Ki Kim, Yoon-Ra Her, Umrao R. Monani

×

Figure 2

Depletion of SMN specifically in skeletal muscle is sufficient to cause pathology.

Options: View larger image (or click on image) Download as PowerPoint
Depletion of SMN specifically in skeletal muscle is sufficient to cause ...
(A) Confocal transverse section image of the calf muscle of a mutant mouse selectively depleted of the SMN protein in skeletal muscle tissue. Muscle cell–autonomous pathology is observed in the form of degenerating fibers penetrated by circulating IgG (asterisks), infiltrating microglia (arrows) and numerous myofibers containing abnormal, centrally positioned nuclei (arrowheads). Muscle was dual stained with antibodies against Iba-1 and mouse IgG to visualize microglia and damaged myofibers, respectively. Scale bar: 50 μm. (B) Kaplan-Meier survival curves depicting the correlation between SMN2 copies, and thus absolute SMN levels, in muscle and life span of the SMA mutants. P < 0.0001, log-rank test, n ≥ 16 mice of each cohort. (C) Enumeration of degenerating myofibers and cells harboring central nuclei in the gastrocnemius of mutants selectively depleted of SMN in skeletal muscle. Roughly nine times as many SMA fibers were found to display central nuclei compared with those that were degenerating (IgG-positive). *P < 0.05, ** P < 0.01, t tests, n ≥ 300 fibers from n ≥ 3 mice of each cohort. Panels adapted from Kim et al. (33).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts